Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 6/20 | 0.36 |
| ▸ | CDK9 | P50750 | 6/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3013040 | 1.00 | CCNT1 (0.36) | CCNT1CDK9CREBBPCDYLMAPT | |
| SCHEMBL8111928 | 1.00 | CCNT1 (0.36) | CCNT1CDK9CREBBPCDYLMAPT | |
| SCHEMBL13667575 | 0.94 | MAPT (0.32) | CCNT1CDK9CREBBPCDYLMAPT | |
| SCHEMBL14287103 | 0.93 | WDR5 (0.36) | CCNT1CDK9CDYLMAPTGAA | |
| SCHEMBL14422908 | 0.91 | GAA (0.40) | CCNT1CDK9CREBBPCDYLMAPT | |
| SCHEMBL14287083 | 0.91 | CCNT1 (0.37) | CCNT1CDK9CREBBPCDYLMAPT | |
| SCHEMBL14287169 | 0.91 | SCN9A (0.37) | CCNT1CDK9CREBBPCDYLMAPT | |
| SCHEMBL14287095 | 0.89 | CDYL (0.41) | CDYLMAPTGAAKDM4EMEN1 | |
| SCHEMBL4352645 | 0.89 | MAPT (0.36) | CDYLMAPTGAAKDM4EMEN1 | |
| SCHEMBL8119153 | 0.89 | CCNT1 (0.36) | CCNT1CDK9SCN9ALRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197721-A1 | PYRROLO [3, 4-h] ISOQUINOLINE COMPOUNDS AND METHODS FOR MODULATING GATED ION CHANNELS | AROS PHARMA APS (DK) | 2010-08-05 | — | — | US | claimed |
| US-7718641-B2 | Pyrrolo [3,4-H] isoquinoline compounds and methods for modulating gated ion channels | AROS PHARMA APS (DE) | 2010-05-18 | — | — | US | claimed |
| US-20090246134-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-10-01 | — | — | US | claimed |
| US-20070191418-A1 | Compositions and methods for modulating gated ion channels | AROS PHARMA APS (DK) | 2007-08-16 | — | — | US | claimed |
| US-20100197721-A1 | PYRROLO [3, 4-h] ISOQUINOLINE COMPOUNDS AND METHODS FOR MODULATING GATED ION CHANNELS | AROS PHARMA APS (DK) | 2010-08-05 | — | — | US | disclosed |
| US-20100197721-A1 | PYRROLO [3, 4-h] ISOQUINOLINE COMPOUNDS AND METHODS FOR MODULATING GATED ION CHANNELS | AROS PHARMA APS (DK) | 2010-08-05 | — | — | US | disclosed |
| US-20100197721-A1 | PYRROLO [3, 4-h] ISOQUINOLINE COMPOUNDS AND METHODS FOR MODULATING GATED ION CHANNELS | AROS PHARMA APS (DK) | 2010-08-05 | — | — | US | disclosed |
| US-7718641-B2 | Pyrrolo [3,4-H] isoquinoline compounds and methods for modulating gated ion channels | AROS PHARMA APS (DE) | 2010-05-18 | — | — | US | disclosed |
| US-7718641-B2 | Pyrrolo [3,4-H] isoquinoline compounds and methods for modulating gated ion channels | AROS PHARMA APS (DE) | 2010-05-18 | — | — | US | disclosed |
| US-7718641-B2 | Pyrrolo [3,4-H] isoquinoline compounds and methods for modulating gated ion channels | AROS PHARMA APS (DE) | 2010-05-18 | — | — | US | disclosed |
| US-20090246134-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-10-01 | — | — | US | disclosed |
| US-20090246134-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-10-01 | — | — | US | disclosed |
| US-20090246134-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-10-01 | — | — | US | disclosed |
| WO-2008144931-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-12-04 | — | — | WO | disclosed |
| US-20070191418-A1 | Compositions and methods for modulating gated ion channels | AROS PHARMA APS (DK) | 2007-08-16 | — | — | US | disclosed |
| WO-2007059608-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191418-A1 | Compositions and methods for modulating gated ion channels | KCNN3, KCNN2, HCN3 | CCNT1 4868/4885CDK9 4231/4885CREBBP 2159/4885 |
| US-20100197721-A1 | PYRROLO [3, 4-h] ISOQUINOLINE COMPOUNDS AND METHODS FOR MODULATING GATED ION CHANNELS | KCNQ1, KCNQ2, KCNH3 | CCNT1 4700/4885CDK9 3650/4885CREBBP 1856/4885 |
| US-20090246134-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | ASIC1, ASIC3, TRPV1 | CCNT1 4864/4885CDK9 4007/4885CREBBP 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.